References
- The National Institute of Neurological Disorders and Stroke rt-PA Study Group. Tissue plasminogen activator for acute ischemic stroke. NEJM 333, 181–188 (1995).
- The IST-collaborative group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]: a randomized trial. Lancet 379, 2352–2363 (2012).
- Hacke W, Kaste M, Bluhmki E et al. Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. N. Engl. J. Med. 359, 1317–1329 (2008).
- Bluhmki E, Chamorro A, Davalos A et al. Stroke treatment with alteplase given 3.0–4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomized controlled trial. Lancet Neurol. 8, 1095–1102 (2009).
- Fiebach JB, Al-Rawi Y, Wintermark M et al. Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase. Stroke 43, 1561–1566 (2012).
- Bivard A, Spratt N, Levi C, Parsons M. Perfusion computer tomography imaging and clinical validation in acute ischaemic stroke. Brain 134, 3435–3440 (2011).
- Albers GW, Thijs VN, Wechsler L et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann. Neurol. 60, 508–517 (2006).
- Lansberg MG, Straka M, Kemp S et al. MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): prospective cohort study. Lancet Neurol. 11, 860–867 (2012).
- Mlynash M, Lansberg MG, De Silva DA et al. DEFUSE-EPITHET Investigators. Refining the definition of the malignant profile: insights from the DEFUSE-EPITHET pooled data set. Stroke 42, 1270–1275 (2011).
- Smith WS, Sung G, Saver J et al. Mechanical thrombectomy for acute ischemic stroke: Final results of the multi merci trial. Stroke 39, 1205–1211 (2008).
- Penumbra Pivotal Stroke Trial Investigators. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke 40, 2761–2768 (2009).
- Saver JL, Jahan R, Levy E et al. Solitaire flow restoration device versus the Merci retriever in patients with acute ischaemic stroke (SWIFT: a randomized parallel-group, non-inferiority trial. Lancet 380, 1241–1249 (2012).
- Nogueira RG, Lutsep HL, Gupta R et al. Trevo versus Merci retrievers for thrombectomy revascularization of large vessel occlusion in acute ischaemic stroke (TREVO 2): a randomized trial. Lancet 380, 1231–1240 (2012).
- Davis SM, Donnan GA, Parsons MW et al. Effects of alteplase beyond 3 h after stroke onset in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): A placebo-controlled randomized trial. Lancet Neurol. 7, 299–399 (2008).
- Ma HK, Zavala JA, Churilov L et al. The hidden mismatch: An explanation for infarct growth with perfusion-weighted imaging/diffusion-weighted imaging mismatch in patients with acute ischemic stroke. Stroke 42, 662–668 (2011).
- Kidwell CS, Jahan R, Gornbein J et al. MR RESCUE Investigators. A trial of imaging selection and endovascular treatment for ischemic stroke. NEJM 368, 904–913 (2013).
- Ma H, Parsons MW, Christensen S et al.; on behalf of the EXTEND investigators. A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int. J. Stroke 7, 74–80 (2012).
- Fisher M, Albers GW. Advanced imaging to extend the therapeutic time window of acute ischemic stroke. Ann. Neurol. 73, 74–78 (2013).